Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-10924
Fritzsche, F R; Jung, M; Tölle, A; Wild, P; Hartmann, A; Wassermann, K; Rabien, A; Lein, M; Dietel, M; Pilarsky, C; Calvano, D; Grützmann, R; Jung, K; Kristiansen, G (2008). ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. European Urology, 54(5):1097-1108.
|PDF - Registered users only|
OBJECTIVES: A disintegrin and metalloprotease (ADAM) 9 has been implicated in tumour progression of prostate cancer. We evaluated the expression of ADAM9 on protein and messenger RNA (mRNA) level in a larger cohort of prostate cancer cases following prostatectomy and correlated the findings with clinicopathological parameters including prostate-specific antigen (PSA) relapse times. METHODS: We immunostained 198 clinicopathologically characterised prostate cancer cases for ADAM9. For 25 additional cases, ADAM9 mRNA of microdissected tumour and normal tissue was analysed via quantitative reverse transcriptase-polymerase chain reaction. RESULTS: ADAM9 was significantly upregulated in prostate cancer compared with normal tissue on mRNA and protein level. ADAM9 protein expression was significantly associated with shortened PSA relapse-free survival in univariate and multivariate analyses, particularly in patients who had received prior androgen ablation. CONCLUSIONS: ADAM9 is overexpressed in prostate cancer cases and is an independent prognostic marker of PSA relapse-free survival following radical prostatectomy. Further studies are needed to verify its role as a predictive marker of response to androgen ablation.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Surgical Pathology|
|DDC:||610 Medicine & health|
|Deposited On:||21 Jan 2009 15:53|
|Last Modified:||23 Nov 2012 14:48|
|WoS Citation Count:||21|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page